SYS6040 / CSPC Pharma - LARVOL DELTA

CSPC PHARMA Anti-tumor Drug SYS6040 Approved by US FDA for Clinical Trials (iis.aastocks.com) - "CSPC PHARMA... announced that the Investigational New Drug (IND) application for SYS6040 (Antibody-Drug Conjugate) developed by the Group has been approved by the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the U.S."

IND • Oncology • Solid Tumor

A Study of SYS6040 for Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=180 | Recruiting | Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.

New P1 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

CSPC Pharmaceutical Group’s SYS6040 (antibody-drug conjugate) has been approved for clinical trials [Google translation] (CSPC Press Release) - "On March 21, CSPC Pharmaceutical Group...announced that SYS6040 (antibody-drug conjugate)...developed by the Group has been approved by the State Food and Drug Administration of the People's Republic of China for clinical trials in China. This product is a monoclonal antibody-drug conjugate that binds to specific receptors on the surface of tumors, enters cells through endocytosis and releases toxins to kill tumor cells. This product is declared as a Class 1 therapeutic biological product, and the approved indication is advanced solid tumors....This product has submitted multiple patent applications at home and abroad."

New trial • Patent • Solid Tumor